11/393. Gabapentin as a promising treatment for antipsychotic-induced movement disorders in schizoaffective and bipolar patients. Improvement of antipsychotic-induced blepharospasm and involuntary oral-mandibulo movements was observed with the use of the anticonvulsant drug gabapentin among 14 of 16 affectively ill patients who had been exposed to maintenance neuroleptics of the conventional type. In many cases, the movement disorders of these patients had not responded to more standard measures such as clozapine. This finding permits a potential strategy for patients with treatment-emergent tardive dyskinesia, a well-known complication of extended conventional neuroleptic use. Gabapentin, whose mood stabilizing properties have been reported in several clinical reports, represents a more natural treatment in the setting of bipolar spectrum disorders. ( info) |
12/393. Two cases of risperidone-induced tardive dyskinesia and a review of the literature. Acase in which a 26 year old patient with undifferentiated schizophrenia, showing abnormal oral, lingual and jaw movements suggestive of tardive dyskinesia during a dose reduction of risperidone, is presented. A second case, relating to a 39 year old married woman diagnosed as having a DSM-IV schizophreniform disorder is also presented. These two cases are discussed in relation to the existing literature. ( info) |
13/393. Case report: Complications of rehabilitation using osseointegrated implants--tardive dyskinesia. The oral rehabilitation of patients using osseointegrated dental implants is a well established treatment modality. However complications can arise during the provision of treatment. This case report describes the management of a patient exhibiting tardive dyskinesia with an implant stabilised mandibular overdenture. Complications of the treatment and their resolution are discussed. ( info) |
14/393. Asterixis induced by gabapentin. We report the case of a patient with postherpetic neuralgia who developed asterixis while being treated with gabapentin. We discuss the possible mechanism of asterixis in this patient. ( info) |
15/393. Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha. A 28 year-old man with chronic hepatitis b was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days. Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly. His akathisia symptoms worsened thereafter. clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia. Two days' administration of levomepromazine 100 mg led him to a coma for 2 days. Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically. He became completely premorbid 2 weeks after administration of levodopa. The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha. ( info) |
16/393. Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine. Rapid improvement of tardive dyskinesia was identified following initiation of olanzapine in an elderly male patient formally treated with chlorpromazine. ( info) |
17/393. Catatonialike symptomatology and withdrawal dyskinesias. The authors describes a patient who presented catatonialike symptoms and dyskinesias associated with glutethimide discontinuance and antihistamine use. He hypothesizes that altered dopamine metabolism may produce some of the unusual neuropsychiatric characteristics of glutethimide withdrawal. Drug-withdrawal catatonia may be an additional entity in the differential diagnosis of catatonialike states of organic etiology. ( info) |
18/393. risperidone implicated in the onset of tardive dyskinesia in a young woman. The aim of this case report is to highlight that risperidone may cause and ameliorate tardive dyskinesia. A 16 year old white women with a 12 month history of schizophrenia, developed buccolingual masticatory tardive dyskinesia after receiving risperidone 6 mg. She had received small dosages of typical antipsychotics before and during receiving risperidone for short periods. Recommencement of risperidone with 2 mg and increasing to 6 mg resulted in improvement in tardive dyskinesia and up until now she remains free of any abnormal involuntary movements. ( info) |
19/393. Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine. In a single inpatient case study, a schizophrenic patient with tardive dyskinesia after prolonged treatment with typical neuroleptics was treated with the new atypical neuroleptic quetiapine, a dibenzothiazepin-derivative. Within 2 weeks of treatment with quetiapine, symptoms of tardive dyskinesia improved; 10 weeks after starting treatment tardive dyskinesia stopped completely. Over the same period, dopamine D2 receptor occupancy decreased substantially, as measured by IBZM-SPECT after 14 and 77 days of treatment. ( info) |
20/393. Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica. In two patients with Parkinson's disease and L-Dopa induced dyskinesia we administered morphine orally to alleviate lumboradicular pain unresponsive to any other form of treatment. Besides an alleviation of the pain both patients showed a decrease in dyskinetic movements at very low doses of morphine and an increase in akinesia at higher doses. This observation indicates a modulation of basal ganglia output by morphine with the possibility of reducing L-Dopa induced dyskinesia in patients treated with morphine for pain. ( info) |